Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
11Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Dogwood Therapeutics, Inc. (DWTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
19Total relationships
3Distinct source URLs
6High confidence
0.736Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Dogwood Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
UNIVERSITY-OF-ALABAMA
UNIVERSITY-OF-ALABAMA
90%
In consideration for the License Agreement, the University of Alabama received membership interests in the Company representing 10% of the issued membership interests at that time.
Reciprocal relationship from ORANY graph: Reciprocal relationship from DWTX graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from DWTX graph: ct which will be distributed to t…
ct which will be distributed to the clinical sites for reconstitution and use in clinical trials. We are presently developing a synthetically formulated version of Halneuron ® to be used for both Pha…
Reciprocal relationship from TNXP graph: arket strategy. Our commercialization strategy for TONMYA is centered on a cost-efficient, targeted sales and marketing approach focused on the top prescribin…
Dogwood Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
PRIDCOR-THERAPEUTICS-LLC
PRIDCOR-THERAPEUTICS-LLC
92%
In exchange, the Company is entitled to a tiered royalty on net sales of up to 15 % upon commercialization of IMC-1 or IMC-2.
Reciprocal relationship from ORANY graph: Reciprocal relationship from DWTX graph: s or the imposition of civil or criminal penalties. The FDA strictly regulates marketing, labeling, advertising and …
s or the imposition of civil or criminal penalties. The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs or devices may be promot…
INNOVATIVE-MED-CONCEPTS-LLC
INNOVATIVE-MED-CONCEPTS-LLC
62%
any”) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, changes in Series A non-voting convertible preferred stock and stockholders’ equity (…
MAXIM-GROUP-LLC
MAXIM-GROUP-LLC
62%
lion related to the Combination with Pharmagesic in October 2024 and a decrease in expenses associated with being a pubic company of $0.2 million offset by increases in salaries and related personnel…
NASDAQ-STOCK-MARKET-LLC
NASDAQ-STOCK-MARKET-LLC
62%
es A Preferred Stock to Sealbond occurred on October 9, 2024. Each share of Series A Preferred Stock is convertible into 10,000 shares of Common Stock, subject to certain conditions described in the …
ORGANIZATION-DOGWOOD-THERAPEUTICS-INC
ORGANIZATION-DOGWOOD-THERAPEUTICS-INC
62%
any”) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, changes in Series A non-voting convertible preferred stock and stockholders’ equity (…
REJUVENATION-LABS-INC
REJUVENATION-LABS-INC
62%
versity of Alabama reserved the right to use the Technical Information for educational, research, clinical, and other non-commercial purposes. We may assign the license to any purchaser or transferee…
SERPIN-PHARMA-INC
SERPIN-PHARMA-INC
62%
versity of Alabama reserved the right to use the Technical Information for educational, research, clinical, and other non-commercial purposes. We may assign the license to any purchaser or transferee…
VIRIOS-THERAPEUTICS-INC
VIRIOS-THERAPEUTICS-INC
62%
any”) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, changes in Series A non-voting convertible preferred stock and stockholders’ equity (…
VIRIOS-THERAPEUTICS-LLC
VIRIOS-THERAPEUTICS-LLC
62%
any”) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, changes in Series A non-voting convertible preferred stock and stockholders’ equity (…
Dogwood Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
DWTX-DEBT-9186
Warrants outstanding: 20000
90%
xbrl warrant detail from xbrl 2022-09-30.
DWTX-DEBT-9187
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
DWTX-DEBT
Debt stack $162,604
90%
Market cache reports total debt of $162,604.
Dogwood Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Dogwood Therapeutics, Inc..
Dogwood Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
DWTX-OWNER-ARMISTICE-CAPITAL-LLC
ARMISTICE CAPITAL, LLC
90%
13F overlay lists ARMISTICE CAPITAL, LLC as top holder; 15 tracked holders.
Dogwood Therapeutics, Inc. Extended Supply Chain Network
